All News

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) for the third-line treatment of patients with advanced small cell lung cancer (SCLC).

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

When and where to mention (or not mention) your ongoing cancer survivorship story?

The Food and Drug Administration granted a priority review to polatuzumab vedotin in combination with bendamustine plus Rituxan (rituximab) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

In an effort to help others understand a breast cancer diagnosis, survivors may choose to use unique words. Sometimes, these words can be offensive.

The Food and Drug Administration (FDA) granted a priority review to entrectinib for the treatment of adult and pediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.

The Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) – an immunotherapy agent – for the treatment of patients with resected, high-risk, stage 3 melanoma.

Event to Fund Cutting-Edge Pediatric Cancer Research

In the patient-centric world of oncology, let's not overlook who stands watch and gives without expecting anything in return.

Writing down our thoughts is a novel idea.

The combination regimen demonstrated improved efficacy outcomes with a tolerable profile among patients with relapsed/refractory mantle cell lymphoma.

I have gotten exceptionally good at worrying about things that never end up happening. I'd say I am failing at worry.

In patients with mantle cell lymphoma, the introduction of BTK inhibitors continues to shape the treatment landscape.

One widow's journey to stay in her home honors her husband's memory and brings healing.

Cancer survivors have tremendous issues and fears to go through after an initial diagnosis. Don't add to your distress or lose sleep over self-blame.

From 240 million-year-old dinosaur tumors to today's top performers and athletes, here is a quick overview of what is making headlines in the cancer space.

The Food and Drug Administration granted a priority review to Keytruda (pembrolizumab) in combination with Inlyta (axitinib) as a frontline treatment for advanced renal cell carcinoma.

Many people struggle with extra weight and cancer survivors often do it with extra helpings of fear and guilt. See if these thoughts can help!

Anxiety before an appointment can be troublesome for a person with cancer. In this post, learn ways to conquer those feelings.

Although they no longer face the disease, adolescent and young adult survivors live with hardships.

One expert weighs in on the use of new immunotherapy agents and combinations in treating non-small cell lung cancer.

What started as a hangnail turned into one of the most difficult late effects of breast cancer. This survivor found swimming to be a viable treatment for her lymphedema.

When Joanne Lam was diagnosed with bladder cancer, her husband showed unwavering devotion in caring for her. Now it's her turn to be his caregiver.

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

Your disease does not make you unworthy, because only the worthy will see past it.

The Food and Drug Administration (FDA) approved a split-dosing regimen for Darzalex (daratumumab) for the treatment of patients with multiple myeloma.

A mastectomy can leave a lasting mark. This breast cancer survivor found her own unique way to make it a beautiful one.

CURE® spoke with CEO Linda Tantawi about addressing the needs of underserved communities and how education is key in helping women in the Greater New York City area.

The Food and Drug Administration granted a priority review to Bavencio (avelumab) in combination with Inlyta (axitinib) to treat patients with advanced renal cell carcinoma (RCC).

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to phase 3 findings published in the New England Journal of Medicine.